tbuckley/cabot-search huggingface dataset:
Relationship between tumor gene expression and recurrence in stage II/III colon cancer: Quantitative RT-PCR assay of 757 genes in fixed paraffin-embedded (FPE) tissue
Authors: M. J. O’Connell, S. Paik, G. Yothers, J. P. Costantino, J. W. Cowens, K. M. Clark, J. Baker, J. Hackett, D. Watson, N. Wolmark
Journal: Journal of Clinical Oncology (2006)

3518 Background: As an initial step in developing abetter method of assessing prognosis following potentially curative surgery for colon cancer, we performed an exploratory gene identification study. Methods: RNA was extracted from three 10-micron sections of the FPE tumor tissue obtained at the initial diagnosis from 353 patients entered between 1977 and 1984 into the surgery-only or surgery-plus BCG arms of NSABP C-01/C-02. Expression was quantified for 757 cancer-related and reference genes with RT-PCR. Results: Blocks from 270 patients were evaluable after pre-specified exclusions: 128 were stage II and 142 were stage III. All patients had ≥ 5-year follow up. In univariate Cox proportional hazard analyses, 148 genes exhibited a nominally significant (unadjusted p-value &lt;0.05) linear association with recurrence-free interval (RFI) (7 genes p≤0.001, 66 genes 0.001&lt;p&lt;0.01; 75 genes 0.01≤p&lt;0.05). False discovery rate calculations suggest that about 25% of the 148 genes are expected to be false positives. Higher expression was associated with shorter RFI for 118 genes including SERPINB5, DUSP1, AKT3, TIMP1, ANXA2, RHOB (p≤ 0.001) and with longer RFI for 30 genes including BRCA1 (p≤0.001). The relationship between gene expression and RFI was similar for stage II and stage III patients for 143 of the 148 genes found to be significant. The largest cluster of genes is functionally related to extracellular matrix remodeling. The magnitude of the hazard ratios is similar to that observed in the early Oncotype DX studies in breast cancer and should allow clinically useful separation into low/intermediate/high risk groups. Conclusions: Quantitative RT-PCR assay of FPE colon cancer tissue can be used to identify large numbers of genes associated with RFI in patients with stage II and III colon cancer. If these results are confirmed by additional studies in progress, this technique has promise to improve selection of colon cancer patients for adjuvant chemotherapy. Funded in part as a collaborative arrangement under contract between the NSABP Foundation, Inc., and Genomic Health, Inc. [Table: see text]
Prediction of long-term survival using expression of FOXA1, a determinant of estrogen response domains in breast cancer
Authors: S. Badve, D. Turbin, A. Morimiya, T. Nielsen, C. Perou, S. Dunn, D. Huntsman, H. Nakshatri
Journal: Journal of Clinical Oncology (2006)

539 Background: Recent studies have demonstrated cofactor dependency of estrogen receptor alpha (ERα) in defining specific pattern of estrogen (E2) response in breast cancer. FOXA1, also called HNF3α, a forkhead family transcription factor, has emerged as a major cofactor that is essential for optimum transcription of ∼50% of ERα:E2 responsive genes. FOXA1 is expressed in breast cancer cells and in cDNA microarray cluster analysis segregates with genes that characterize the luminal A subtype such as ERα, GATA3, and XBP-1. Detailed expression analysis of FOXA1 in human breast tumors has not been previously performed and it is not known whether it is an independent prognostic factor in breast cancer. Methods: A tissue microarray comprising tumors from 438 patients with 20 years follow-up was analyzed for FOXA1 expression using goat-anti-human FOXA1 antibody by immunohistochemistry. Percentage (P) and intensity (I) of expression was analyzed to generate numerical score (S= P × I). FOXA1 expression was correlated with tumor grade, nodal status, disease free survival, and expression of ER, PR, GATA3, HER2, p27 kip1 , phospho-AKT, and luminal A subtype (defined as ER &amp;/or PR+, bcl-2+ and Her-2-neg). Results: FOXA1 expression (score greater than 100) was seen in 187 of 438 breast cancers and correlated with greater likelihood of survival at 20 year (p=0.0114). A significant positive correlation was observed between FOXA1 expression and expression of ERα (p= 0.000001), GATA3 (p= 0.000001), PR (p= 0.00001), phospho-AKT (p= 0.00001). Similarly, a significant correlation was noted with luminal A subtype. An inverse correlation was noted with tumor grade and mdm-2 expression (p=0.00001). HER2 or p27 kip1 expression and nodal status showed no correlation with FOXA1. Conclusions: FOXA1 is good prognostic marker predicting disease free survival in patients with breast cancer. Since its expression correlates well with breast cancer of luminal A subtype, it can also be used to identify these good prognosis tumors from the rest of the ER positive breast cancers in archival paraffin embedded breast tissues. No significant financial relationships to disclose.
TCT-189 Comparison of 5-year Clinical Outcomes between Stabilized Acute Myocardial Infarction Patients following Percutaneous Coronary Intervention and the Patients with Angina Pectoris
Authors: Ju Yeol Baek, Seung-Woon Rha, Byoung Geol Choi, Jae Kyeong Byun, Se Yeon Choi, Jun Hyuk Kang, Woo Hyeun Kim, Ja Yeon Choi, James Hall, Sung Hun Park, SunKi Lee, Hu Li, Jin Oh Na, Cheol Ung Choi, Jin Won Kim, Hong Euy Lim, Eung Ju Kim, Chang Gyu Park, Hong-Seog Seo, Dong Joo Oh
Journal: Journal of the American College of Cardiology (2016)
PS01.47: PET Volumetric Prognostic Index may be the Most Significant Survival Factor in Non–Small Cell Lung Cancer Treated with Chemoradiation
Authors: Li Yan, Hong Zhang, Maurice King, Huanmei Wu, Colin Huang, Wenhu Pi, Yonglin Pu, Mark Tan, Feng-Ming (Spring) Kong
Journal: Journal of Thoracic Oncology (2016)
Differences in Clinical and Functional Outcomes of Atrial Fibrillation in Women and Men
Authors: En Lin Goh, Swathikan Chidambaram
Journal: JAMA Cardiology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
TCT-276 Prevalence and 5-Year Outcomes of Full Metal Jacket Drug-Eluting Stenting for Coronary Chronic Total Occlusion
Authors: Pil Hyung Lee, Seung-Whan Lee, Jung-Min Ahn, Duk-Woo Park, Soo-Jin Kang, Young-Hak Kim, Cheol Whan Lee, Seong-Wook Park, Seung-Jung Park
Journal: Journal of the American College of Cardiology (2016)
TCT-115 Clinical features and Outcomes in patients with Acute Coronary Syndrome Complicated by Cardiogenic Shock supported with Extracorporeal Membrane Oxygenation, Single Center Experience
Authors: Sungsoo Cho, Geun Young Cho, Dongmin Kim, Seong-Hoon Lim, Tae Soo Kang, Byoung Eun Park, Myung-Yong Lee
Journal: Journal of the American College of Cardiology (2016)
Ischemic Forms of Venous Thrombosis—Phlegmasia Cerulea Dolens; Venous Gangrene.
Authors: H Haimovici
Journal: Annals of Internal Medicine (1971)

severe circulatory disturbances of the extremities secondary to venous thrombosis which are covered by a variety of terms, including phlegmasia cerulea dolens. Of the 230 pages, 73 are taken up with extensive tables listing individual cases of venous occlusion and adding little if anything to the substance of the text. Such space would more profitably have been used for more of the excellent photographs which are already present in the text but in small number. Although the author distinguishes between the various types of venous thrombosis and between venous thrombosis and arterial embolism in the chapter on diagnosis, the earlier discussions shift too rapidly back and forth between the different types of
Opioids in COPD: a cause of death or a marker of illness severity?
Authors: James Downar, Rebecca Colman, Robert Horton, Paul Hernandez, Graeme Rocker
Journal: European Respiratory Journal (2016)

In a recent issue of the European Respiratory Journal , Vozoris et al. [1] reported a study showing an association between opioid use and increased mortality in patients with chronic obstructive pulmonary disease (COPD). The authors concluded that these results were "worrisome", and cautioned readers about the "potential for adverse respiratory outcomes" when using opioids in patients with COPD. We are concerned about the authors' interpretation of their data, and the implication that the use of opioids is dangerous in this population. Opioid use associated with mortality in COPD, but dyspnoea-targeted opioids are safe and effective (and good practice) <http://ow.ly/EHiu302ST5O>
Drug resource use and costs for novel agents in multiple myeloma.
Authors: Gary Binder, William N. Harwin, Stephen Stemkowski, Yunping Zhou, Zeba M. Khan, Ali Nourbakhsh
Journal: Journal of Clinical Oncology (2012)

e18560 Background: Lenalidomide plus dexamethasone and bortezomib are NCCN guideline-recommended treatments for multiple myeloma (MM). While several economic models have assessed these regimens (Fullerton AMCP 2007, Durie IMW 2011), there is a lack of published real-world evidence on payer drug costs, particularly regarding billed unit quantities. This analysis evaluated utilization quantities per claim and incurred payer costs for a common time period for lenalidomide and bortezomib in MM. Methods: A retrospective claims analysis was conducted using pharmacy and medical claims data from a large US payer. Claims for 5 million Medicare Advantage (MA) and commercial plan members continuously and non-continuously enrolled within the period 07/01/2009 to 06/30/2011 were evaluated to select patients having at least 2 medical claims for MM (ICD9 203.0x), and at least 1 claim for units of these drugs, to identify billed unit quantity and allowed charges per claim. Results: 1,249 patients had MM diagnoses and use of these drugs. The MA and commercial populations had similar utilization and costs. For bortezomib, average quantity billed per claim was 3.3 mg (94% of a full 3.5 mg/10 mL single-use vial); 78% of claims billed 3.5mg. For lenalidomide, average and most common quantity billed per claim was 21 capsules at an average strength of 17.1 mg; the most common strength was 25 mg (43%). Average allowed charges for a common 28-day month were $7,031 for bortezomib (applied over 28 days at $1,318 per each of 4 administrations per 21-day cycle) vs. $6,911 for lenalidomide. Conclusions: Billed and paid utilization for commercial and Medicare Advantage MM patients was generally 1 full vial of bortezomib and 21 capsules of lenalidomide per date of service. Drug costs per month of lenalidomide and bortezomib treatment were very similar, differing by less than $10/day, prior to physician administration charges. Future cost analyses should consider these rates and focus on total drug and medical costs of care, factoring in actual treatment episodes and evaluating common time periods.
Association Between Method of Prescribing and Primary Nonadherence to Dermatologic Medication in an Urban Hospital Population
Authors: Adewole S. Adamson, Elizabeth A. Suarez, April R. Gorman
Journal: JAMA Dermatology (2016)

Prescription underuse is associated with poorer clinical outcomes. A significant proportion of underuse is owing to primary nonadherence, defined as the rate at which patients fail to fill and pick up new prescriptions. Although electronic prescribing increases coordination of care and decreases errors, its effect on primary nonadherence is less certain.To analyze factors associated with primary nonadherence to dermatologic medications and study whether electronic prescribing affects rates of primary nonadherence.A retrospective review of medical records was conducted from January 1, 2011, to December 31, 2013, among a cohort of new patients prescribed dermatologic medications at a single, urban, safety-net hospital outpatient dermatology clinic.The primary outcome was the overall rate of primary nonadherence, defined as filling and picking up all prescribed medications within a 1-year period, and the difference in primary nonadherence between patients who received electronic prescriptions and those who received paper prescriptions. Secondary outcomes included the association of primary nonadherence with sex, age, relationship status, primary language, race/ethnicity, and number of prescriptions.A total of 4318 prescriptions were written for 2496 patients (mean [SD] age, 47.7 [13.2] years; 849 men and 1647 women). The overall rate of primary nonadherence was 31.6% (n = 788). Based on multivariable analysis, the risk of primary nonadherence was 16 percentage points lower among patients given an electronic prescription (15.2%) than patients given a paper prescription (31.5%). Primary nonadherence decreased with age (<30 y, 38.9%; 30-49 y, 35.3%; and 50-69 y, 26.3%), and then increased in elderly patients 70 years and older (31.9%). Of patients who were given 1, 2, 3, 4, or 5 prescriptions, rates of primary nonadherence were 33.1%, 28.8%, 26.4%, 39.8%, and 38.1%, respectively. Primary nonadherence decreased with age but then increased in elderly patients. Patients identifying English as their primary language had the highest rate of primary nonadherence (33.9%) compared with Spanish (29%) or other speakers (20.4%).Compared with paper prescriptions, electronic prescriptions were associated with less primary nonadherence. Number of prescriptions, language, race/ethnicity, and age were associated with increased rates of primary nonadherence. Efforts must be made to understand why primary nonadherence occurs, identify patients prone to primary nonadherence, and simplify medication regimens to maximize adherence and quality of care.
The Impact of Cytogenetics on the Outcomes of Treatment with Lenalidomide Plus Dexamethasone in Relapsed or Refractory Multiple Myeloma.
Authors: Nizar J Bahlis, Kevin W. Song, Tommy Fu, Birgitte J Roland, Hong Chang, Doug Horsman, Adnan Mansoor, Christine Chen, Esther Masih- Khan, Young Trieu, Helene Bruyere, Douglas A. Stewart, Donna E. Reece
Journal: Blood (2008)
Efficacy and Safety of VTE Prophylaxis with Oral Rivaroxaban Compared to Fondaparinux or Low-Molecular Weight Heparin In a Large Cohort of Consecutive Patients Undergoing Major Orthopaedic Surgery
Authors: Jan Beyer-Westendorf, Lars Donath, Jörg Lützner, Sebastian Werth, Oliver Radke, Klaus-Peter Guenther, Norbert Weiss
Journal: Blood (2011)
Treatment with Anti-CD19 BiTE® Blinatumomab in Adult Patients with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (r/r ALL) Post-Allogeneic Hematopoietic Stem Cell Transplantation
Authors: Anthony Selwyn Stein, Max S. Topp, Hagop M Kantarjian, Nicola Goekbuget, Ralf C Bargou, Mark R Litzow, Alessandro Rambaldi, Josep Ribera, Alicia Zhang, Zachary Zimmerman, Stephen J. Forman
Journal: Blood (2015)
Radiation in pediatric Hodgkin's disease [In Process Citation]
Authors: JJ Shuster, PW Geiser
Journal: Journal of Clinical Oncology (1998)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1998.16.1.393a Journal of Clinical Oncology - published online before print September 21, 2016 Radiation in pediatric Hodgkin's disease [In Process Citation] JJ ShusterxJJ ShusterSearch for articles by this author , PW GeiserxPW GeiserSearch for articles by this author https://doi.org/10.1200/JCO.1998.16.1.393a PDF "Radiation in pediatric Hodgkin's disease [In Process Citation]." Journal of Clinical Oncology, 16(1), p. 393a© 1998 by American Society of Clinical Oncology
ATPS-40FUNCTIONAL ROLES OF CD166/ALCAM IN GLIOBLASTOMA
Authors: Noriyuki Kijima, Naoki Hosen, Naoki Kagawa, Naoya Hashimoto, Manabu Kinoshita, Haruo Sugiyama, Toshiki Yoshimine
Journal: Neuro-Oncology (2015)

Prognosis of glioblastoma multiforme (GBM) patients still remains poor.To improve its prognosis, it is important to identify new therapeutic targets.CD166/ALCAM is a member of the immunoglobulin superfamily and is widely expressed in various tissues such as neurons, fibroblasts, endothelial cells.Furthermore it is also reported to be a colon cancer stem cell marker as well as mesenchymal stem cell marker.CD166/ALCAM is also expressed on endothelial cells and is involved in angiogenesis.In this study, we aim to analyze the functional roles of CD166/ALCAM in glioblastoma.Transfection of CD166/ALCAM siRNA to U87MG and U251 cells significantly increased cell invasion in matrigel invasion assay without affecting cell proliferation.Transfection of ALCAM shRNA to U87MG glioblastoma cells significantly increased the tumor vessel area of U87MG xenograft in immune-deficient mice.Furthermore, over-expression of soluble isoform of CD166/ALCAM in U87MG GBM cells promoted tumor progression in intracranial transplant to immune-deficient mice.We also found that CD166/ ALCAM was highly expressed on the CD133 + glioblastoma stem cell populations.In the CD133 + glioblastoma cell population, CD166/ALCAM positive cells were highly enriched with tumor-sphere-initiating cells in vitro.In summary, CD166/ALCAM is involved in glioblastoma invasion, angiogenesis, and tumor progression in glioblastoma.In addition CD166/ALCAM can be a candidate for glioblastoma progenitor markers.All these findings suggest that CD166/ALCAM is a potent therapeutic target against glioblastoma.
Final Results from the Phase IIa Study of the Anti-CXCL12 Spiegelmer® Olaptesed Pegol (NOX-A12) in Combination with Bortezomib and Dexamethasone in Patients with Multiple Myeloma
Authors: Heinz Ludwig, Katja Weisel, Maria Teresa Petrucci, Xavier Leleu, Anna Maria Cafro, Garderet Laurent, Niklas Zojer, Robin Foa, Richard Greil, Ibrahim Yakoub-Agha, Anna Kruschinski, Thomas Dümmler, Kai Riecke, Monika Engelhardt
Journal: Blood (2014)
Innate lymphoid cells in allergic and nonallergic inflammation
Authors: Hideaki Morita, Kazuyo Moro, Shigeo Koyasu
Journal: Journal of Allergy and Clinical Immunology (2016)

In the last decade, the full picture of the role of innate lymphoid cells (ILCs) has been gradually revealed. ILCs are classified into 3 groups based on their transcription factors and cytokine production patterns, which mirror helper T-cell subsets. Unlike T cells and B cells, ILCs do not have antigen receptors. They promptly respond to multiple tissue-derived factors, such as cytokines and alarmins, and produce multiple proinflammatory and immunoregulatory cytokines. It has been reported that ILC-derived cytokines are important for the induction and regulation of inflammation. Accumulating evidence suggests that ILCs play substantial roles in protection against infection and the pathogenesis of inflammatory diseases, such as allergic diseases and autoimmune diseases. Different ILC subsets localize in distinct tissue/organ niches and receive tissue-derived signals on different types of inflammation, which allows them to acquire diverse phenotypes with specialized effector capacities. In this review we highlight the roles of ILCs in a variety of organs, such as the airway, skin, and gastrointestinal tract, in the context of allergic and nonallergic inflammation.
HLA Alloantibody Persistence and De Novo Production of HLA Alloantibodies of Donor Origin Following Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation.
Authors: Ross M Fasano, Sharon Adams, Aleah Smith, Theresa Donohue, Charles D. Bolan, Kyoko Sugimoto, Willy A. Flegel, Richard Childs
Journal: Blood (2010)
Donor Toll-Like Receptor 9 Genetic Factors in Susceptibility to Acute Graft-Versus-Host Disease and Cytomegalovirus Infection After Related and Unrelated Hematopoietic Stem Cell Transplantation
Authors: Haowen Xiao, Yi Luo, Xiaoyu Lai, Jimin Shi, Yamin Tan, Jingsong He, Wanzhuo Xie, Weiyan Zheng, Li-Mengmeng Wang, Shan Fu, Lifei Zhang, Xiujin Ye, Xiaohong Yu, Zhen Cai, Maofang Lin, He Huang
Journal: Blood (2012)
Comparative Effectiveness Research on the Treatment Outcomes of Subcutaneous (SC) and Intravenous (IV) Bortezomib (BTZ) in Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts)
Authors: Robert M. Rifkin, Esprit Ma, Robyn Harrell, Yanyan Zhu, Edward Dow, Liviu Niculescu, Vijayveer Bonthapally
Journal: Blood (2015)
Roles of Raf/MEK/ERK and PI3K/Akt/mTOR Pathways in Prevention of Apoptosis and Induction of Drug Resistance in Myeloid Hematopoietic Cells.
Authors: Steve L. Abrams, Camilla Evangelisti, Francesca Chiarini, Negin Misaghian, Jorg Basecke, Michele Millela, Agostino Tafuri, Massimo Libra, Franca Stivala, Marina Konopleva, Michael Andreeff, Linda S. Steelman, Jacob Troppmair, Alberto M. Martelli, James A. McCubrey
Journal: Blood (2007)
Rituximab Added to CODOX-M/IVAC Is Highly Effective in HIV-Negative and hiv-Positive Burkitt Lymphoma
Authors: Jeremy S. Abramson, Jeffrey A. Barnes, Christiana E. Toomey, Eric D. Jacobsen, Philippe Armand, Tak Takvorian, David C. Fisher, Hazel Reynolds, Ephraim P. Hochberg, Ann S. LaCasce
Journal: Blood (2008)
Deoxycytidine Kinase Genotype Influences Leukemia Cell Concentration of Cytarabine 5′-Triphosphate in Pediatric AML Patients.
Authors: Jatinder Lamba, Kristine Crews, Stanley Pounds, Erin Schuetz, Varsha Gandhi, William Plunkett, Jeffrey Rubnitz, Raul Ribeiro
Journal: Blood (2007)